[Guideline on urothelial carcinoma of the bladder]
| Autor: | Rob F M, Bevers, Jan J, Battermann, Jourik A, Gietema, Christina A, Hulsbergen-Van de Kaa, Theo M, de Reijke, Nicole, Feller, J A Fred, Witjes |
|---|---|
| Jazyk: | Dutch; Flemish |
| Rok vydání: | 2010 |
| Předmět: |
Carcinoma
Transitional Cell Urology Brachytherapy Antineoplastic Agents Cystoscopy Urinary Diversion Combined Modality Therapy Neoadjuvant Therapy Administration Intravesical Urinary Bladder Neoplasms Humans Lymph Node Excision Cisplatin Neoplasm Recurrence Local Practice Patterns Physicians' Carcinoma in Situ Hematuria Netherlands |
| Zdroj: | Nederlands tijdschrift voor geneeskunde. 153 |
| ISSN: | 1876-8784 |
| Popis: | Urothelial carcinoma of the bladder is diagnosed predominantly in people over 60 years of age. The most common symptom is haematuria. Smoking is an important risk factor (relative risk 2.5 to 3). Cystoscopy is performed whenever bladder carcinoma is suspected. The recurrence rate of a non-muscle invasive urothelial carcinoma is high (31-78% within 5 years). A single intravesical instillation with a chemotherapeutic agent within 24 hours of transurethral resection (TUR) reduces the risk of recurrence. Carcinoma in situ (CIS) should be treated as high-grade urothelial carcinoma. Standard treatment for patients with non-metastasized muscle-invasive urothelial carcinoma is cystectomy in combination with extensive lymph node dissection. There are several possibilities for urinary diversion following cystectomy, none of which are any better than the others. Bladder-sparing brachytherapy may be used in patients with solitary T1 - T2 urothelial carcinoma5 cm. Neoadjuvant cisplatin-containing chemotherapy prior to cystectomy in muscle-invasive carcinoma only slightly improves survival. Cisplatin-containing combination chemotherapy is the standard treatment for metastasized urothelial carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|